Physician profile
Kyle Uto
NPI 1982274585
$924.54
in general payments reported to CMS, 2019-2025
14 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.09 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $184.16 | 2025 | Airsupra |
| Novo Nordisk INC | $94.72 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $91.77 | 2025 | Mounjaro, Jardiance |
| Pfizer INC. | $69.53 | 2025 | |
| Sumitomo Pharma America, INC. | $61.73 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $49.97 | 2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $48.34 | 2025 | |
| Astellas Pharma US INC | $39.21 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $20.30 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.61 | 2025 | Givlaari |
| Abbott Laboratories | $17.87 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $15.59 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Uto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.